Business Context and Reporting Period
Allogene Therapeutics, Inc. filed this Form 8-K on September 21, 2022, reporting an event dated September 15, 2022, under Item 8.01, “Other Events.” The filing concerns Servier’s discontinuation of its involvement in developing licensed CD19 products, including UCART19, ALLO-501, and ALLO-501A.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other quantitative financial results. It does disclose the following potential economic effects:
- Allogene may elect an option to obtain rights to the CD19 products outside the United States.
- If Allogene exercises the option, potential milestone payments related to ALLO-501A would increase by €46 million in aggregate for first dosing in Phase 2, first dosing in Phase 3, and regulatory approval.
- If the option is exercised, Allogene would no longer be able to recover 40% of development costs for the CD19 products from Servier.
Material Changes Versus Prior Period
Servier provided notice that it was discontinuing its involvement in development of all licensed CD19 products. The discontinuation does not otherwise affect Allogene’s existing exclusive U.S. license for development and commercialization of those products, but it creates a potential decision regarding non-U.S. rights and changes the associated cost-sharing and milestone economics if Allogene elects those rights.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Servier requested that Allogene exercise the non-U.S. option within a limited timeframe, although the Servier Agreement does not require Allogene to do so.
- If Allogene does not exercise the option within Servier’s requested timeframe, Allogene expects to continue relying on Servier to perform its contractual obligations.
- Servier’s failure to perform could require legal enforcement efforts, increasing costs and diverting management resources; the outcome of any enforcement action would be uncertain.
- Servier licenses certain CD19 rights from Cellectis and sublicenses them to Allogene. Cellectis has challenged certain Servier performance and Servier’s ability to grant a worldwide sublicense.
- Unresolved challenges by Cellectis could materially adversely affect Allogene’s business, financial condition, and prospects and could further strain the relationships among the parties.
- The filing contains forward-looking statements regarding the option, future actions, and the relationships among Allogene, Servier, and Cellectis. The company undertakes no obligation to update those statements.
Important Facts for Investors to Verify
- Whether Allogene exercises the Ex-U.S. Option and the applicable decision deadline.
- The continuing enforceability and scope of Allogene’s U.S. rights under the Servier Agreement.
- Whether Cellectis’s challenges are resolved and whether Servier continues to satisfy its contractual obligations.
- The impact of any option exercise on future milestone obligations and loss of reimbursement for 40% of development costs.
- Subsequent filings for any changes to development plans, collaboration arrangements, litigation, or financial exposure related to the CD19 products.